Mirvie
Mirvie utilizes a proprietary RNA analysis platform to predict pregnancy complications, such as preeclampsia and preterm birth, months before symptoms arise through a simple blood test. This technology provides critical insights into the unique biological changes of each pregnancy, enabling timely interventions for improved maternal-fetal health outcomes.
- Artificial Intelligence
- Digital Health
- Healthcare Technology
- Software Only
Funding
Raised to date
$90.3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Maneesh Jain
CEO
Product
Problem
Current methods for detecting pregnancy complications like preeclampsia and preterm birth often rely on the appearance of symptoms, which limits the window for effective intervention. This late detection can lead to crisis management scenarios, impacting maternal and fetal health outcomes.
Solution
Mirvie offers a predictive platform that analyzes RNA messages in a pregnant woman's blood to identify potential complications months before symptoms manifest. By examining tens of thousands of RNA messages from the baby, placenta, and mother, the platform gains insights into the unique biological changes occurring during pregnancy. This allows for proactive and personalized care, enabling timely interventions to improve the well-being of both mother and baby. The platform aims to transform pregnancy care by providing a new window into pregnancy health, allowing doctors to intervene before complications escalate.
Target Audience
The primary audience includes obstetricians, maternal-fetal medicine specialists, and healthcare providers focused on improving pregnancy outcomes.
Features
- RNA analysis platform assessing tens of thousands of RNA messages from mother, baby, and placenta.
- Machine learning models to predict pregnancy complications based on underlying biology.
- Early prediction of preeclampsia and preterm birth months before symptoms appear.
- Non-invasive blood test for easy and accessible screening.
- Ongoing clinical research to validate and enhance platform performance.